Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease.

Roberts RL, Wallace MC, Seinen ML, van Bodegraven AA, Krishnaprasad K, Jones GT, van Rij AM, Baird A, Lawrance IC, Prosser R, Bampton P, Grafton R, Simms LA, Studd C, Bell SJ, Kennedy MA, Halliwell J, Gearry RB, Radford-Smith G, Andrews JM, McHugh PC, Barclay ML.

Inflamm Bowel Dis. 2018 May 16. doi: 10.1093/ibd/izy163. [Epub ahead of print]

PMID:
29788244
2.

Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR.

J Crohns Colitis. 2018 May 25;12(6):653-661. doi: 10.1093/ecco-jcc/jjy003.

PMID:
29385469
3.

Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.

Chartier LC, Howarth GS, Lawrance IC, Trinder D, Barker SJ, Mashtoub S.

Dig Dis Sci. 2018 Jan;63(1):135-145. doi: 10.1007/s10620-017-4876-4. Epub 2017 Dec 6.

PMID:
29214422
4.

Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method.

Chen GB, Lee SH, Montgomery GW, Wray NR, Visscher PM, Gearry RB, Lawrance IC, Andrews JM, Bampton P, Mahy G, Bell S, Walsh A, Connor S, Sparrow M, Bowdler LM, Simms LA, Krishnaprasad K; International IBD Genetics Consortium, Radford-Smith GL, Moser G.

BMC Med Genet. 2017 Aug 29;18(1):94. doi: 10.1186/s12881-017-0451-2.

5.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ; International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC.

Nature. 2017 Jul 13;547(7662):173-178. doi: 10.1038/nature22969. Epub 2017 Jun 28.

6.

Dysplasia and colorectal cancer surveillance in inflammatory bowel disease.

Pulusu SSR, Lawrance IC.

Expert Rev Gastroenterol Hepatol. 2017 Aug;11(8):711-722. doi: 10.1080/17474124.2017.1327347. Epub 2017 May 16. Review.

PMID:
28475382
7.

Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis.

Lawrance IC, Baird A, Lightower D, Radford-Smith G, Andrews JM, Connor S.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1248-1255. doi: 10.1016/j.cgh.2017.02.027. Epub 2017 Mar 7.

PMID:
28286194
8.

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.

Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL; Australian and New Zealand Inflammatory Bowel Disease Consortium.

Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. doi: 10.1111/apt.13880. Epub 2016 Dec 19.

PMID:
27995633
9.

Serologic antibodies in relation to outcome in postoperative Crohn's disease.

Hamilton AL, Kamm MA, De Cruz P, Wright EK, Selvaraj F, Princen F, Gorelik A, Liew D, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Bell SJ, Brown SJ, Connell WR.

J Gastroenterol Hepatol. 2017 Jun;32(6):1195-1203. doi: 10.1111/jgh.13677.

PMID:
27976801
10.

Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.

Baird AC, Mallon D, Radford-Smith G, Boyer J, Piche T, Prescott SL, Lawrance IC, Tulic MK.

World J Gastroenterol. 2016 Nov 7;22(41):9104-9116.

11.

High Vitamin D-Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease.

Ghaly S, Murray K, Baird A, Martin K, Prosser R, Mill J, Simms LA, Hart PH, Radford-Smith G, Bampton PA, Lawrance IC.

Inflamm Bowel Dis. 2016 Oct;22(10):2456-64. doi: 10.1097/MIB.0000000000000894.

PMID:
27631600
12.

Review article: acute severe ulcerative colitis - evidence-based consensus statements.

Chen JH, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TW, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-Smith G, Lawrance IC, McLachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group.

Aliment Pharmacol Ther. 2016 Jul;44(2):127-44. doi: 10.1111/apt.13670. Epub 2016 May 26. Review.

13.

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.

Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-Smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ.

Gastroenterology. 2016 Jul;151(1):110-9. doi: 10.1053/j.gastro.2016.04.002. Epub 2016 Apr 8.

PMID:
27063728
14.

The multidisciplinary team.

Lawrance IC.

J Gastroenterol Hepatol. 2016 Jun;31 Suppl 1:17. doi: 10.1111/jgh.13351. No abstract available.

PMID:
26991134
15.

Acute severe ulcerative colitis: Changing treatment paradigms.

Lawrance IC.

J Gastroenterol Hepatol. 2016 Jun;31 Suppl 1:16. doi: 10.1111/jgh.13350. No abstract available.

PMID:
26991023
16.

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC; International Inflammatory Bowel Disease Genetics Consortium, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW.

Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. Epub 2015 Oct 18.

17.

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.

Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ.

Aliment Pharmacol Ther. 2015 Nov;42(10):1170-81. doi: 10.1111/apt.13398. Epub 2015 Sep 23.

18.

Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits S, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV.

Aliment Pharmacol Ther. 2015 Oct;42(7):867-79. doi: 10.1111/apt.13353. Epub 2015 Aug 28.

19.

Indications and selection of MR enterography vs. MR enteroclysis with emphasis on patients who need small bowel MRI and general anaesthesia: results of a survey.

Torkzad MR, Masselli G, Halligan S, Oto A, Neubauer H, Taylor S, Gupta A, Frøkjær JB, Lawrance IC, Welman CJ, Negård A, Ekberg O, Patak M, Lauenstein T.

Insights Imaging. 2015 Jun;6(3):339-46. doi: 10.1007/s13244-015-0384-2. Epub 2015 Apr 9.

20.

Effect of intestinal resection on quality of life in Crohn's disease.

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV.

J Crohns Colitis. 2015 Jun;9(6):452-62. doi: 10.1093/ecco-jcc/jjv058. Epub 2015 Apr 8.

PMID:
25855073
21.

Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.

Lawrance IC.

Expert Opin Investig Drugs. 2015 Jun;24(6):761-8. doi: 10.1517/13543784.2015.1020371. Epub 2015 Feb 26. Review.

PMID:
25719407
22.

Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function.

Baird AC, Lloyd F, Lawrance IC.

Dig Dis Sci. 2015 Jun;60(6):1603-16. doi: 10.1007/s10620-015-3552-9. Epub 2015 Jan 29.

PMID:
25630423
23.

Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB.

Gastroenterology. 2015 May;148(5):938-947.e1. doi: 10.1053/j.gastro.2015.01.026. Epub 2015 Jan 22.

PMID:
25620670
24.

Crohn's disease management after intestinal resection: a randomised trial.

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV.

Lancet. 2015 Apr 11;385(9976):1406-17. doi: 10.1016/S0140-6736(14)61908-5. Epub 2014 Dec 24.

PMID:
25542620
25.

Mechanisms of initiation and progression of intestinal fibrosis in IBD.

Latella G, Di Gregorio J, Flati V, Rieder F, Lawrance IC.

Scand J Gastroenterol. 2015 Jan;50(1):53-65. doi: 10.3109/00365521.2014.968863. Review.

PMID:
25523556
26.

Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.

Ghaly S, Costello S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, Antoniades S, Headon B, Connor S, Lawrance IC, Sparrow M, Walsh AJ, Andrews JM; AIBDA.

Intern Med J. 2015 Feb;45(2):170-7. doi: 10.1111/imj.12621.

PMID:
25370691
27.

Cellular and Molecular Mediators of Intestinal Fibrosis.

Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G.

J Crohns Colitis. 2017 Dec 4;11(12):1491-1503. doi: 10.1016/j.crohns.2014.09.008.

28.

HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, Annese V, Bampton P, Barnardo M, Bell S, Cole A, Connor SJ, Creed T, Cummings FR, D'Amato M, Daneshmend TK, Fedorak RN, Florin TH, Gaya DR, Greig E, Halfvarson J, Hart A, Irving PM, Jones G, Karban A, Lawrance IC, Lee JC, Lees C, Lev-Tzion R, Lindsay JO, Mansfield J, Mawdsley J, Mazhar Z, Parkes M, Parnell K, Orchard TR, Radford-Smith G, Russell RK, Reffitt D, Satsangi J, Silverberg MS, Sturniolo GC, Tremelling M, Tsianos EV, van Heel DA, Walsh A, Watermeyer G, Weersma RK, Zeissig S, Rossjohn J, Holden AL; International Serious Adverse Events Consortium; IBD Pharmacogenetics Study Group, Ahmad T.

Nat Genet. 2014 Oct;46(10):1131-4. doi: 10.1038/ng.3093. Epub 2014 Sep 14.

PMID:
25217962
29.

Preventing infective complications in inflammatory bowel disease.

Mill J, Lawrance IC.

World J Gastroenterol. 2014 Aug 7;20(29):9691-8. doi: 10.3748/wjg.v20.i29.9691. Review.

30.

Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.

Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Lawrance IC.

J Crohns Colitis. 2014 Oct;8(10):1147-65. doi: 10.1016/j.crohns.2014.03.008. Epub 2014 Apr 14. Review.

31.

What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Lawrance IC.

World J Gastroenterol. 2014 Feb 7;20(5):1248-58. doi: 10.3748/wjg.v20.i5.1248. Review.

32.

Detection of liver injury in IBD using transient elastography.

Thin LW, Lawrance IC, Spilsbury K, Kava J, Olynyk JK.

J Crohns Colitis. 2014 Jul;8(7):671-7. doi: 10.1016/j.crohns.2013.12.006. Epub 2014 Feb 13.

PMID:
24529605
33.

Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.

Gibson PR, Vaizey C, Black CM, Nicholls R, Weston AR, Bampton P, Sparrow M, Lawrance IC, Selby WS, Andrews JM, Walsh AJ, Hetzel DJ, Macrae FA, Moore GT, Weltman MD, Leong RW, Fan T.

J Crohns Colitis. 2014 Jul;8(7):598-606. doi: 10.1016/j.crohns.2013.11.017. Epub 2013 Dec 15.

PMID:
24345767
34.

The importance of validating proposed genetic profiles in IBD.

Lawrance IC.

J Intern Med. 2014 May;275(5):481-3. doi: 10.1111/joim.12180. Epub 2014 Jan 11. No abstract available.

35.

Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice.

Chua AC, Klopcic BR, Ho DS, Fu SK, Forrest CH, Croft KD, Olynyk JK, Lawrance IC, Trinder D.

PLoS One. 2013 Nov 6;8(11):e78850. doi: 10.1371/journal.pone.0078850. eCollection 2013.

36.

Secreted protein acidic and rich in cysteine (SPARC) exacerbates colonic inflammatory symptoms in dextran sodium sulphate-induced murine colitis.

Ng YL, Klopcic B, Lloyd F, Forrest C, Greene W, Lawrance IC.

PLoS One. 2013 Oct 21;8(10):e77575. doi: 10.1371/journal.pone.0077575. eCollection 2013.

37.

Prevention of cancer in IBD - a balancing act.

Mill J, Lawrance IC.

Minerva Gastroenterol Dietol. 2013 Sep;59(3):261-72.

PMID:
23867946
38.

Crohn's disease and smoking: is it ever too late to quit?

Lawrance IC, Murray K, Batman B, Gearry RB, Grafton R, Krishnaprasad K, Andrews JM, Prosser R, Bampton PA, Cooke SE, Mahy G, Radford-Smith G, Croft A, Hanigan K.

J Crohns Colitis. 2013 Dec;7(12):e665-71. doi: 10.1016/j.crohns.2013.05.007. Epub 2013 Jun 20.

PMID:
23790611
39.

Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era.

Thin LW, Murray K, Lawrance IC.

Inflamm Bowel Dis. 2013 Jun;19(7):1490-8. doi: 10.1097/MIB.0b013e318281f362.

PMID:
23615528
40.

Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.

Walsh AJ, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, Radford-Smith G, Selby W, Veillard AS, Grimm MC, Travis SP, Lawrance IC.

J Crohns Colitis. 2013 Nov;7(10):e449-56. doi: 10.1016/j.crohns.2013.02.019. Epub 2013 Apr 17.

PMID:
23601754
41.

Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's disease.

Doecke JD, Simms LA, Zhao ZZ, Huang N, Hanigan K, Krishnaprasad K, Roberts RL, Andrews JM, Mahy G, Bampton P, Lewindon P, Florin T, Lawrance IC, Gearry RB, Montgomery GW, Radford-Smith GL.

Inflamm Bowel Dis. 2013 Feb;19(2):240-5. doi: 10.1097/MIB.0b013e3182810041.

PMID:
23348120
42.

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH.

Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.

43.

A validated bowel-preparation tolerability questionnaire and assessment of three commonly used bowel-cleansing agents.

Lawrance IC, Willert RP, Murray K.

Dig Dis Sci. 2013 Apr;58(4):926-35. doi: 10.1007/s10620-012-2449-0. Epub 2012 Oct 25.

PMID:
23095990
44.

Microbiota and management of inflammatory bowel disease.

Lawrance IC.

J Gastroenterol Hepatol. 2012 Jul;27(7):1137-40. doi: 10.1111/j.1440-1746.2012.07163.x. No abstract available.

PMID:
22712707
45.

Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease.

Lawrance IC.

Expert Opin Investig Drugs. 2012 Jul;21(7):975-84. doi: 10.1517/13543784.2012.690030. Epub 2012 May 22. Review.

PMID:
22612537
46.

Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study.

Krishnaprasad K, Andrews JM, Lawrance IC, Florin T, Gearry RB, Leong RW, Mahy G, Bampton P, Prosser R, Leach P, Chitti L, Cock C, Grafton R, Croft AR, Cooke S, Doecke JD, Radford-Smith GL.

J Crohns Colitis. 2012 Apr;6(3):287-93. doi: 10.1016/j.crohns.2011.08.016. Epub 2011 Oct 4.

PMID:
22405164
47.

SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.

Chew A, Salama P, Robbshaw A, Klopcic B, Zeps N, Platell C, Lawrance IC.

PLoS One. 2011;6(7):e22047. doi: 10.1371/journal.pone.0022047. Epub 2011 Jul 26.

48.

Novel topical therapies for distal colitis.

Lawrance IC.

World J Gastrointest Pharmacol Ther. 2010 Oct 6;1(5):87-93. doi: 10.4292/wjgpt.v1.i5.87.

49.

Bowel cleansing for colonoscopy: prospective randomized assessment of efficacy and of induced mucosal abnormality with three preparation agents.

Lawrance IC, Willert RP, Murray K.

Endoscopy. 2011 May;43(5):412-8. doi: 10.1055/s-0030-1256193. Epub 2011 May 4.

PMID:
21547879
50.

NOD2 and CD.

Lawrance IC.

Inflamm Bowel Dis. 2011 Dec;17(12):2596-7. doi: 10.1002/ibd.21727. Epub 2011 Apr 20. No abstract available.

PMID:
21509912

Supplemental Content

Loading ...
Support Center